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Abstract Fungal endocarditis (FE) is an uncommon
disease, and while accounting for only 1.3–6% of all cases
of infectious endocarditis, it carries a high mortality risk.
Although Candida albicans represents the main etiology of
FE, C. parapsilosis is the most common non-albicans
species. We report the case of a 32-year-old man with a
history of prior intravenous drug (IVD) use hospitalized
with endocarditis due to C. parapsilosis and review all 71
additional cases documented in the literature. A retrospec-
tive analysis of the 72 C. parapsilosis cases compared to 52
recently reviewed cases of C. albicans endocarditis was
conducted to identify organism-specific clinical peculiarities.
The most common predisposing factor for C. parapsilosis
endocarditis (41/72; 57.4%) involved prosthetic valves
followed by IVD use (12/72; 20%). Peripheral embolic
and/or hemorrhagic events occurred in 28/64 (43.8%)
patients, mostly in cerebral and lower limb territories.
Overall mortality was 41.7%. Combined surgical and clinical
treatment was associated with a lower mortality. Few patients
received the newer antifungal agents, and it would appear
that more experience is required for their use in the treatment
of C. parapsilosis endocarditis.
Introduction
Although fungal endocarditis (FE) accounts for only 1.3–6%
of all infective endocarditis cases, it carries a high mortality
risk and has increased in incidence over the last two decades
[1, 2]. The latter may be explained by improved diagnostic
methods, a greater exposure to medical therapies that
predispose to fungal infection, an increase in the incidence
of intravenous drug (IVD) use and a more frequent use of
invasive procedures for diagnosis and therapy [1, 3]. Fungal
endocarditis is associated with a higher incidence of
embolic events than bacterial endocarditis. An additional
diagnostic challenge is that some common clinical signs
and symptoms of endocarditis, including the presence of
cardiac murmurs, may be absent [4].
The incidence of invasive candidiasis has increased during
the past years [5], with Candida species being the most
common agents involved in fungal endocarditis, followed by
Aspergillus species. In a review of 152 cases of FE, Candida
spp. was responsible for 94.1% of yeast endocarditis and
Aspergillus spp. for 71.8% of mold endocarditis [1]. Among
yeast-related endocarditis, C. albicans was the most frequent
strain isolated (46%), followed by C. parapsilosis (17%).
The latter was the most common pathogen isolated in IVD
users [4]. Candida parapsilosis is also associated with
nosocomial infections related to vascular devices, which
may be explained in part by its ability to produce a biofilm
on foreign bodies and catheters [6].
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We report here a case of relapsing C. parapsilosis
endocarditis in an IVD user-patient and review the
additional 71 cases published in the literature. A compar-
ison of outcome differences with 52 C. albicans endocar-
ditis cases was also conducted with the aim of identifying
organism-specific clinical peculiarities.
Materials and methods
We conducted an OVID-MEDLINE search without lan-
guage restriction from January 1968 through October 2006
to identify cases published in any language. The keywords
“Candida parapsilosis”, “endocarditis” and “fungal endo-
carditis” were used. Additional references were retrieved
from reviews on the topic. Only reports with sufficient
information on epidemiological and clinical data for
patients over 16 years old were included. The review was
also restricted to cases of “definite infective endocarditis”
according to the modified Duke’s criteria [7].
To evaluate potential clinical and epidemiological
disagreement, the 72 cases of C. parapsilosis endocarditis
were compared with 52 cases of C. albicans endocarditis
recently reviewed [1].
Collected data were recorded in a database especially
designed for the study. Analyses were performed by chi-
square test, Fisher’s exact test, and Student’s t test, as
appropriate. Two-sided tests were used and p<0.05 was
considered to be statistically significant. In the multivariate
analysis, the dependent variable was mortality, and only
variables with a p<0.2 in terms of outcome were included
in a stepwise logistic regression model. Calculations were
made using the EPIINFO statistical program, ver. 3.3.2
(Centers for Disease Control and Prevention, Atlanta, GA).
Case report
A 32-year-old man with a history of prior IVD use was
hospitalized with acute thromboembolic stroke and C.
parapsilosis candidemia. Transoesophageal echocardiogra-
phy (TEE) revealed a 6-mm-sized floating vegetation in the
aortic valve. In view of the intermediary susceptibility to
fluconazole presented by the blood isolate of C. para-
psilosis (MIC4 mg/l), combined therapy with caspofungin
[70 mg intravenous (i.v.) as first day loading dose, followed
by 50 mg/day i.v.] and voriconazole [800 mg daily (p.o.)
first day loading dose, followed by 400 mg/d p.o.] was
administered for 12 weeks. The patient refused a surgical
aortic valve replacement and was discharged with a
proposed suppressive therapy of voriconazole (400 mg/day
p.o), but was subsequently lost to follow-up. Three months
after hospital discharge, he was re-hospitalized due to an
episode of thromboembolic ischemic stroke linked to relapsed
C. parapsilosis endocarditis. The patient acknowledged non-
compliance to the voriconazole treatment previously pre-
scribed. Voriconazole (400 mg/day p.o.) was restarted. A
new TEE showed a vegetation in the aortic valve associated
with a perforation and a mycotic aneurysm in the right
coronary cuspid. A moderate to severe valve insufficiency
was also found. In view of these findings and the severe
hemodynamic compromise, the decision was taken to replace
the aortic valve by a porcine xenograft valve (Schilling N° 25).
The post-operative period was uneventful, and the patient was
discharged from the hospital under voriconazole therapy
(400 mg/day p.o.) – and again was lost to follow-up. One year
following surgery, the patient was re-admitted with severe
cardiac failure due to severe aortic insufficiency associated
with paravalvar leak. He admitted to having followed the
antifungal treatment for only 4 months following his last
discharge. Blood cultures yielded C. parapsilosis once again,
and a TEE revealed vegetations in the aortic prosthetic valve.
The patient died suddenly two days after admission. The
authorization to perform the autopsy was not given.
Results
Including our own case, we retrieved a total of 80 cases of
endocarditis due to C. parapsilosis. Of these, 72 met the
inclusion criteria (Appendix). Most cases were published
prior to the availability of the newer antifungal compounds,
such as echinocandins and second-generation triazoles.
Clinical presentation, risk factors and complications
Of the 72 patients meeting the inclusion criteria of this
review, 71% (51/72) were male, and the mean age was
48.73 years (±15.8 years). Forty-one (57%) patients had
isolated prosthetic valve involvement, and 31 (48.6%) had
isolated native valve involvement; in four subjects, both
native and prosthetic (relapsing infection) valve involve-
ment occurred. Globally, the most frequent predisposing
factor was prior cardiac surgery for valve replacement (57%)
(Table 1). Late-onset infection, defined here as 6 months
following surgery, occurred in 21/33 (63.3%) patients with
prosthetic valve involvement for whom data were available.
The second most frequent predisposing factor was IVD use
(12/72 patients; 16.6%). Eleven of the 72 patients (15.2%)
presented simultaneously with more than one predisposing
factor. An absence of predisposing factors was observed in
only 4/72 (5.6%) patients.
Data on embolic or hemorrhagic complications were
available for 64 (88.8%) of the 72 patients. Of these, 28
(43.8%) presented complications, with the most common
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sites being the lower limbs (ten; 35.7%) and the brain (six;
21.4%), followed by the lung (three; 10.7%) and the upper
limbs (two; 7.1%). Seven (25%) of 28 patients presented
intracranial hemorrhage, probably secondary to mycotic
aneurysms.
Table 1 summarizes the characteristics of the 52 reported
cases of C. albicans [1] and the 72 cases of C. parapsilosis
endocarditis. The latter showed a trend towards a more
frequent history of prior parenteral nutrition and valvular
disease.
Therapy and outcome
Single, combined or sequential medical antifungal therapy
was received by 28 (38.0%), 25 (34.7%) and 16 (22.2%)
patients, respectively. Amphotericin B deoxycholate was
the most frequently prescribed antifungal drug in 41
patients (56.9%), followed by 5-fluocytosine (23 patients;
31.9%) and fluconazole (20 patients; 27.7%). Other
antifungal treatments were lipid formulations of amphoter-
icin B (six patients; 8.3%) and miconazole and ketocona-
zole (five patients; 6.9%). Five patients were treated with
the newer antifungal drugs caspofungin (three patients;
4.1%) and voriconazole (two patients; 2.7%). Medical
treatment was not specified in two cases (2.7%). Combined
surgical and medical treatment was performed in 42/72
(58.3%) patients. Interestingly, surgical therapy was more
commonly performed in native valve patients (72.4%) than
in patients with prostheses [45.7%; Odds Ratio (OR) 3.1;
95% confidence interval (CI) 1.0–8.9; p=0.05].
Neither mean age nor gender was associated with
outcome. A trend was observed toward a higher mortality
among patients with C. parapsilosis endocarditis less than
65 years (OR 3.18; 95%CI 0.85–11.83; p=0.07). Of note,
this was restricted to patients that underwent cardiac
surgery (OR 5.2; 95%CI 0.81–32.98; p=0.08).
The mortality rate was lower among patients undergoing
adjunctive surgical therapy (33.3%) than among those
treated only with antifungals (53.3%), but the difference
was not statistically significant (OR 0.4; 95%CI 0.2–1.1;
p=0.14). Surgery was not related to a lower incidence of
embolic and/or hemorrhagic complications, which were
observed in 43.9% of surgical-associated therapy and 40.9%
of the non-surgical cases (OR 1.1; 95% CI 0.4–3.2; p=0.96).
This result could be due to the higher incidence of embolic
events in the early course of FE.
Even in a multivariate analysis adjusted for gender, age
(two blocks; ≥ or < than 65 years), combined surgical
Table 1 Main predisposing factors, age, associated mortality rate and affected valves observed in 124 reported cases of Candida parapsilosis and
C. albicans endocarditisa
C. albicans C. parapsilosis OR (95% CI) p value
n Percentage n Percentage
Number of patients 52 72
Predisposing factors
Prosthetic valve 29 55.8 41 57 0.95 (0.4–2.0) 0.94
IVD use 4 7.7 12 16.6 0.42 (0.1–1.5) 0.23
Intravenous parenteral nutrition 0 0.0 5 6.9 0 (0–1.58) 0.06
Broad spectrum antibiotics 1 1.9 4 5.6 0.33 (0–3.3) 0.29
Abdominal surgery 4 7.7 5 6.9 1.12 (0.2–5.1) 0.56
Previous valvular disease 7 13.5 3 4.8 3.58 (0.8–18.5) 0.06
Immunosuppressionb 5 9.6 4 6.4 1.81 (0.4–8.6) 0.30
Other 3 5.6 3 4.1 1.41 (0.2–9.2) 0.49
None 2 3.8 4 5.6 0.68 (0.1–4.6) 0.50
Mean age (years±SD) 42.5 14.2 43.8 14.7 - -
Mortality rate 17 33 30 41.7 - -
Valve
Aortic 27 51.9 41 56.9 - -
Mitral 14 26.9 21 29.1 - -
Tricuspid 5 9.6 3 4.1 - -
Combination 6 11.5 - - - -
Ventricular wall - - 2 2.8 - -
Pulmonary - - 1 1.4 - -
OR, Odds ratio; 95% CI, 95% confidence interval; IVD, intravenous drug
aMore than one predisposing factor may be present for each patient
b Includes one case of esophageal cancer, one case of allogenic bone marrow transplantation, one case of advanced HIV infection and to cases of
diabetes
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therapy or not and type of valve (native or prosthetic), an
adjuvant surgical treatment was significantly associated
with a better outcome (OR 0.3; 95% CI 0.1–1.0; p=0.05)
(Table 2).
Discussion
The first case of endocarditis due to C. parapsilosis was
reported in 1940 [8]. In the years that followed, this agent
was predominantly reported as an etiology of endocarditis,
notably in IVD users [9]. However, C. parapsilosis is now
considered to be an important emerging pathogen of
invasive candidiasis, only surpassed by C. albicans [10],
and this will probably have consequences on FE microbi-
ology in the near future [11, 12]. C. parapsilosis strains
associated with invasive disease are more likely to produce
biofilm structures [13] that are morphologically different
from those produced by C. albicans [14].
Recent changes in fungal epidemiologymay also be related
to the wide use of azoles in combination with the new
prophylactic and therapeutic strategies for fungal infections.
More specifically, there is a consensus that the percentage of
Candida non-albicans species accounting for nosocomial
Candida infections is increasing, in part due to the
widespread use of fluconazole [15]. The most probable
source of infection in the outbreaks of C. parapsilosis
infective endocarditis reported to date was determined to be
intraoperative contamination (e.g. cardiac bypass equipment,
tears in surgical gloves worn by carrier surgeons) [16, 17].
The core findings of this review reveal that the aortic
valve was the most commonly involved valve, with 42.5%
of cases occurring in native valves. The most common
predisposing factor in patients with native valve involve-
ment was IVD use. Overall mortality among these patients
was as high as 41.7%, with a lower mortality among those
treated with adjuvant surgery. Only five cases treated with
new antifungal drugs have been reported to date, which
precludes the drawing of any firm conclusion on their role
in the treatment of C. parapsilosis endocarditis.
Only four (5.7%) patients did not present any predis-
posing factor for C. parapsilosis endocarditis. However,
Rubinstein and Lang reported that as high as 12% of
patients presenting with FE have no identifiable predispos-
ing factors [18]. In general, the predisposing factors
observed were similar to those of patients with endocarditis
due to C. albicans [19]. A comparison of C. albicans and
C. parapsilosis endocarditis cases shows that FE due to
these pathogens rarely originates without a predisposing
factor and occurs more frequently in prosthetic valves. In
addition, a history of IVD use was present in 20% of
patients with C. parapsilosis infection. In contrast, C.
albicans seems to be less frequently associated with IVD
use and is observed predominantly in patients with underly-
ing abnormal valves, mostly with rheumatic disease (Table 1).
Our data suggest also that C. parapsilosis is more prevalent
than C. albicans in patients receiving parenteral nutrition
(Table 1).
Embolic and/or hemorrhagic complications were present
in 43.8% of patients, most commonly as cerebral thrombo-
embolic events, which is in accordance with the incidence
rate reported by Ellis et al. [4]. In general, the occurrence of
embolic events in patients with fever should always be seen
as a potential diagnostic of infective endocarditis. In
particular, a fungal etiology must be considered, given the
high likelihood of thromboembolic events reported in these
cases [20].
Survival in patients with FE is poor and barely exceeds
50% [18]. Although C. parapsilosis endocarditis has been
associated with a higher mortality when compared to
endocarditis caused by other Candida species [19], this
could not be confirmed in our comparison with C. albicans
cases (Table 1).
The ideal treatment for Candida endocarditis has not
been formally tested in prospective randomized controlled
studies. In the present review, combined surgical and
medical therapy was associated with a lower mortality rate.
In clinical practice, surgery is generally regarded as the
standard treatment for FE. The American College of
Cardiology (ACC) and The American Heart Association
(AHA) guidelines stipulate surgical indications for FE
(Class I recommendation). In addition, the recent Infectious
Diseases Society of America (IDSA) guidelines on Candida
endocarditis recommend that it should be treated by valve
replacement, either for native or prosthetic valves [21].
Unfortunately, the heterogeneity of the population affected,
allied to the relative rarity of FE, makes the performance of
prospective studies impractical [4].
Retrospective studies based on well-documented cases
may be a feasible alternative. In their recent meta-analysis,
Steinbach et al. suggest that patients who underwent
combined surgical and medical therapy may have presented
a lower mortality rate (OR 0.56; 95% CI 0.16–1.99). A higher
Table 2 Variables associated with mortality in 64a patients presenting
with endocarditis due to C. parapsilosis: multivariate analysis
OR 95% CI p value
Age (≥ or <65 years) 0.34 0.08–1.45 0.14
Gender 1.0 0.29–3.39 0.99
Adjuvant surgery 0.33 0.01–1.02 0.05
Type of valve (native or prosthetic) 0.56 0.17–1.82 0.34
a Eight patients were excluded from the analysis: four patients without
data on the type of involved valve and four patients with sequential
native and prosthetic valve involvement
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mortality has been reported in patients infected by C.
parapsilosis (OR 1.51; 95%CI 0.39–5.52) and with left-
sided endocarditis (OR 2.36, 95%CI 0.55–10.07) [19].
However, methodological limitations should be considered
when analyzing these results. For example, in very critically
ill patients, a surgical procedure may be precluded, thus
leading to a falsely higher mortality in the group with
medical treatment alone. Moreover, a high number of
patients with FE probably underwent surgery because
endocarditis due to these agents are more frequently related
per se to the classical indications for surgical treatment, such
as thromboembolic events and the presence of large
vegetations [22]. In the present review, thromboembolic
events may have commonly indicated a surgical procedure,
which explains why operated patients did not present a lower
incidence of this complication in a cross-sectional analysis.
Finally, isolated reports show that a single medical treatment
for Candida endocarditis may be sufficient – in particular if
the most potent and less toxic antifungal drugs are used [23].
We observed a lower mortality rate among patients that
underwent adjuvant surgery. Multivariate analysis revealed
that this tendency persisted even with adjustment for type
of valve (native or prosthetic), gender and age (≥ or < than
65 years). However, there was a lack of data for
determining if patients treated with surgery had more
severe disease and also on the delay between the diagnosis
of endocarditis and the surgical procedure.
Since the mid-1990s, new antifungal drugs, such as
second-generation triazoles (voriconazole and posacona-
zole), have become available which are well tolerated and
active against fluconazole-less susceptible or fluconazole-
resistant Candida species and which reach high body tissue
concentrations, including in the central nervous system.
Echinocandins (caspofungin, anidulafungin and micafungin),
which have an innovative mechanism of action, are rapidly
fungicidal for Candida species and are rarely associated with
adverse events [24]. They present a good activity in the
biofilm, which could be considered of interest in terms of FE
in patients with prosthetic valves. Candida parapsilosis is
less susceptible to echinocandins, but the clinical impact of
the in vitro results have still to be evaluated [25]. However,
apart from the lack of well-controlled clinical studies using
these new compounds, high costs and the risk of resistance
among fungal species are potential concerns for their
widespread use. An early diagnosis allied to rapid and
efficient treatment may potentially improve the outcome of
FE.
This study presents some of the limitations that are
common to retrospective studies. First, there is an important
heterogeneity among included patients, and the clinical
management of cases was not uniform. Second, data on
patients treated with the new antifungal compounds are
scarce, thus precluding any definitive conclusion. Finally,
given that some of the relevant information is lacking in the
reports, the retrospective analysis of treatments with the aim
of comparing single medical or combined medical plus
surgical treatment remains limited.
Conclusions
More experience is required with the use of newer
antifungal agents in the treatment of C. parapsilosis
endocarditis. These drugs may permit more efficient
therapy since they are related to a higher efficacy and
fewer side effects. As a result, the indication for surgical
therapy may be reduced. Prospective randomized studies
are required to answer these questions, although their
feasibility is uncertain.
Table 3 Details of 71 previously reported cases of Candida parapsilosis (1968–2006)
Authors Reference Age Gendera Type
of
valveb
Valvec Predispositiond Concomitant
surgery
Medical therapye Outcome Complications
Abgueguen
et al. 2002
[1] 81 M P Ao Prosthetic
valve and
long-term
antibiotic
therapy and
abdominal
surgery
Yes Amp B +
fluconazole
Dead No
Aoyagi
et al. 1989
[2] 56 M N Mi and Ao Absent Yes Unspecified drug Survival No
Auger
et al. 1983
[3] 49 M P Mi Prosthetic
valve
Yes Amp B, then
5-FC
Survival Ischemic stroke
Appendix
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Table 3 (continued)
Authors Reference Age Gendera Type
of
valveb
Valvec Predispositiond Concomitant
surgery
Medical therapye Outcome Complications
Baddour 1995 [4] 45 M P Ao Prosthetic
valve and
abdominal
surgery
No Amp B, then
Amp B lipidic
complex, then
fluconazole
(long-term
suppressive
therapy)
Survival No
Blinkhorn
et al. 1992
[5] 37 M N Ao IVD Yes Valve
replacement
and
embolectomy
and Amp B +
5-FC
Survival Lower limbs
embolism
Brandstetter and
Brause 1980
[6] 24 M N Ao IVD Yes Valve
replacement +
mp B and 5-FC
Survival No
Cancelas
et al. 1994
[7] 35 F N Mi Allogeneic
bone marrow
transplant
Yes Amp B, then
fluconazole
(twice)
Survival No
Caparrós and
Cabrera 2002
[8] 48 M N Ao Long-term
antibiotic
therapy
Yes Embolectomy +
liposomal
Amp B
Dead Lower limbs
embolism
Cheng and Yu.
1970
[9] 29 M N and
P
Mi and Tri Cardiac
surgery
Prosthetic
valve
Yes Valve
replacement
Dead Ischemic stroke
and pulmonary
embolism
(autopsy)
Chuei-Shiun Li [10] 53 M P Mi Diabetes
mellitus
Yes Amp B Survival Ischemic stroke
Czwerwiec
et al. 1993
[11] 58 M P Ao Prosthetic
valve
No Amp B, then
fluconazole
(long-term
suppressive
therapy)
Survival Intracerebral
hemorrhage
Darwazah
et al. 1999
[12] 67 M P Ao Prosthetic
valve
Yes Valve
replacement +
liposomal Amp
B and 5-FC
Survival Ischemic stroke
De Belder
et al. 1989
[13] 44 M N Ao Ruptured
oesophagus
and
consequent
surgery
Yes Amp B and 5-FC Survival Ischemic stroke
Diekema
et al. 1997
[14] 79 M P Ao Prosthetic
valve
Yes Amp B Dead No
Diekema
et al. 1997
[14] 70 M P Ao Prosthetic
valve
No Amp B Survival No
Diekema
et al. 1997
[14] 58 M P Ao Prosthetic
valve
No Amp B Dead No
Diekema
et al. 1997
[14] 78 M P Ao Prosthetic
valve
No Amp B Dead No
Dismukes
et al. 1973
[15] 47 NR P Ao Prosthetic
valve
No Amp B Dead NR
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Table 3 (continued)
Authors Reference Age Gendera Type
of
valveb
Valvec Predispositiond Concomitant
surgery
Medical therapye Outcome Complications
Galgiani
et al. 1977
[16] 36 M N and
P
Ao Prosthetic
valve
Yes
(three
times)
Amp B, then
5FC, then Amp
B + 5FC
Dead No
Galgiani
et al. 1977
[16] 50 M P Aortic IVD and
prosthetic
valve
Yes (twice) Amp B, then
5FC, then Amp
B and 5FC,
then miconazol
Dead No
Garzoni
et al. 2006
NP 32 M N and
P
Aortic IDU and
ancient
abdominal
surgery
Yes Voriconazol and
caspofungin,
then
voriconazol
Dead Ischemic stroke
Girmenia
et al. 1996
[17] NR NR NR NR Hematological
malignancy
No Amp B, then
fluconazole
Survival NR
Girmenia
et al. 1996
[17] NR NR NR NR Hematological
malignancy
No Fluconazole Survival NR
Gladstone
et al. 1976
[18] 31 M N Mitral IVD No Amp B and 5-FC Survival Lower limbs
embolism
Gomes
et al. 1976
[19] 55 M N Aortic IVD Yes Amp B and 5-FC Survival No
Gottlieb
et al. 1974
[20] 23 M N Aortic IVD and
bicuspid
aortic valve
Yes Amp B Dead Intracerebral
hemorrhage
Grehl
et al. 1972
[21] 51 M P Aortic Prosthetic
valve
Yes (twice) Amp B ,
then 5-FC
indefinitely
Survival No
Herling
et al. 1984
[22] 67 F N Aortic Prosthetic
valve
Yes Valve
replacement +
Amp B
Survival No
Hoeprich
et al. 1974
[23] 20 F N Aortic IVD and
cardiac
surgery other
No 5-FC, then Amp
B and
clotrimoxazol
Dead No
Inoue
et al. 1998
[24] 57 M N Aortic Parenteral
nutrition
chemotherapy
and
abdominal
surgery
Yes Fluconazole Survival No
Isalska
et al. 1988
[25] 37 F P Mitral Prosthetic
valve
No Amp B, then
Amp B and
5FU, then
fluconazole
Survival Intracerebral
hemorrhage
Johnston
et al. 1994
[26] 68 M P Aortic Prosthetic
valve
No Amp B + 5-FC,
then
ketoconazole
Dead NR
Johnston
et al. 1994
[26] 41 F P Aortic Prosthetic
valve
No Amp B Dead NR
Johnston
et al. 1994
[26] 53 M P Aortic Prosthetic
valve
No Amp B + 5-FC Dead NR
Johnston
et al. 1994
[26] 65 M P Aortic Prosthetic
valve
No Amp B + 5-FC Dead NR
Johnston
et al. 1994
[26] 78 F P Aortic Prosthetic
valve
No Amp B Dead NR
Jones
et al. 2002
[27] 82 M P Ao Prosthetic
valve
Yes Amp B Dead Lower and upper
limb embolism
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Table 3 (continued)
Authors Reference Age Gendera Type
of
valveb
Valvec Predispositiond Concomitant
surgery
Medical therapye Outcome Complications
Jones
et al. 2002
[27] 59 M P Ao Prosthetic
valve
Yes Amp B, then
liposomal Amp
B and 5-FC,
then
fluconazole
Survival No
Kaloterakis
et al. 2003
[28] 59 M N Tri Parenteral
nutrition
antibiotic
therapy
Yes Liposomal Amp
B, then
fluconazole
Survival No
Kontou-
Kastellanou
et al. 1990
[29] 27 M P Ao Prosthetic
valve
Yes Valve
replacement
and Amp B
Survival No
Lejko-Zupanc
and Kozelj
1977
[30] 62 M P Mi Prosthetic
valve
No Amp B, then
fluconazole
Survival No
Li et al. 2004 [10] 53 M N Ao Diabetes
mellitus and
dental
manipulation
Yes Amp B Survival Ischemic stroke
Lipton
et al. 1984
[31] NR F N Mi IVD No Amp B Survival Intracerebral
hemorrhage
López-Ciudad
et al. 2006
[32] 59 F N Ventricular
wall
Abdominal
surgery
Parenteral
nutrition and
antibiotic
therapy
No Caspofungin and
voriconazole
Survival No
Lozano
et al. 1994
[33] 26 M N Ao IVD Yes Fibrinolysis +
Amp B and
5-FC
Survival Lower limb
embolism
Martin
et al. 1979
[34] 30 M N Ao IVD Yes Amp B and 5-FC Survival No
Martin
et al. 1987
[35] 67 F P Mi Prosthetic
valve
Yes Valve
replacement +
Amp B, then
ketoconazole,
then
miconazole.
Dead NO
Mayrer
et al. 1978
[36] 43 M N Mi IVD No Amp B + 5-FC Survival No
Melgar
et al. 1997
[37] 47 M N Ao Absent Yes Amp B, then
ketoconazol,
then amp B,
then
fluconazole
Survival No
Melgar
et al. 1997
[37] 47 F P Mi Prosthetic
valve
Yes Amp B, then
fluconazole
Survival No
Moudgal 2005 [38] 51 M P Ao Prosthetic
valve
No Amp + 5 FU,
then
caspofungin +
fluconazole,
then Amp B
lipid complex
Survival No
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Table 3 (continued)
Authors Reference Age Gendera Type
of
valveb
Valvec Predispositiond Concomitant
surgery
Medical therapye Outcome Complications
Otaki and
Kitamura 1993
[39] 55 F P Mi Prosthetic
valve
Yes Fluconazole Dead Intracerebral
hemorrhage
Record
et al. 1971
[40] 57 M P Ao Prosthetic
valve
No Amp B, then
5FC
Dead Intracerebral
hemorrhage
Rubenstein
et al. 1975
[41] 42 M N Ao No Yes Amp B Dead No
Rubenstein
et al. 1975
[41] 17 M N Mi Rheumatic
heart disease
Yes Amp B Dead Ischemic stroke
Rubenstein
et al. 1975
[41] 42 M P Mi IVD No Amp B and 5FU Dead Intracranial
haemorrhage
Rubenstein
et al. 1975
[41] 62 F N Mi Cardiac
surgery other
No Amp B Dead Upper limb
embolism
Rubenstein
et al. 1975
[41] 35 F N Tri Rheumatic
heart disease
No Amp B Dead Pulmonary
embolism
Rudd
et al. 1980
[42] 53 F P Ao Prosthetic
valve
Yes Amp B Survival Lower limb
embolism
Saito
et al. 2001
[43] 72 M N Tri Parenteral
nutrition
No Amp B and
fluconazole
Survival No
Samelson
et al. 1980
[44] 36 F N and
P
Mi Intervertebral
disc prosthetic
valve
Yes Different drug
therapies: Amp
B, 5-FC,
miconazole
and
ketoconazole
Survival Ischemic stroke,
cerebral
abscess, septic
thrombophlebitis
Senba
et al. 1992
[45] 56 M N Mi No Yes Valve
replacement +
fluconazol and
miconazole
Survival No
Severo
et al. 1987
[46] 33 M P Mi Cardiac
surgery
Prosthetic
valve
No Ketoconazole Dead Ischemic stroke
Stulz
et al. 1980
[47] 34 F P Mi Prosthetic
valve
Yes Amp B Survival No
Sunazawa
et al. 1995
[48] 42 F N Pul Cardiac
surgery other
Yes Unspecified drug Survival No
Tonomo
et al. 2004
[49] 22 M NR VW Abdominal
surgery
antibiotic
therapy and
parenteral
nutrition
Yes Miconazol, then
fluconazole
intercalated
with
miconazol.
Survival Pulmonary
embolism
Veraldi
et al. 2000
[50] 29 F N Ao HIV infection Yes Valve
replacement +
surgical
embolectomy +
Amp B
alternated with
fluconazole
Survival Lower limb
embolism
Vivas
et al. 1985
[51] 54 M N Mi Rheumatic
heart disease
No Amp B Dead No
Wallbridge
et al. 1993
[52] 58 M P Mi Prosthetic
valve
No Amp B and 5FC,
then
fluconazole
Dead No
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